|Home | About | Journals | Submit | Contact Us | Français|
Changes in the brain's cholinergic receptor systems underlie several neuropsychiatric disorders, including Alzheimer's disease, schizophrenia, and depression. An emerging preclinical literature also reveals that acetylcoholine may have an important function in addictive processes, including reward, learning, and memory. This study was designed to assess alterations in cholinergic receptor systems in limbic regions of abstinent cocaine-addicted subjects compared with healthy controls. On three separate days, 23 1- to 6-week abstinent, cocaine- (and mostly nicotine-) addicted subjects and 22 sex-, age-, and race-matched control subjects were administered the muscarinic and nicotinic cholinergic agonist physostigmine, the muscarinic antagonist scopolamine, and saline. Regional cerebral blood flow (rCBF) after each infusion was determined using single photon emission-computed tomography. Both cholinergic probes induced rCBF changes (p<0.005) in relatively distinct, cholinergic-rich, limbic brain regions. After physostigmine, cocaine-addicted subjects showed altered rCBF, relative to controls, in limbic regions, including the left hippocampus, left amygdala, and right insula. Group differences in the right dorsolateral prefrontal cortex, posterior cingulate, and middle temporal gyrus were also evident. Scopolamine also revealed group differences in the left hippocampus and right insula as well as the posterior cingulate and middle temporal gyrus. Cocaine addicted and controls differ in their subcortical, limbic, and cortical response to cholinergic probes in areas relevant to craving, learning, and memory. Cholinergic systems may offer a pharmacologic target for cocaine addiction treatment.
Acetylcholine (ACh) mediates reinforcement, satiation, the acquisition of conditional associations that underlie drug craving and drug sensitization, the development of stimulus response associations in habit learning, and drug procurement through its effects on arousal and attention (Williams and Adinoff, 2008). In addition, ACh and its target receptors are prominent in subcortical and cortical structures important to drug reward, self-administration, and the addictive use of substances. For example, the effect of ACh on reward-relevant processes is due, at least in part, to ACh projections on ventral tegmental area dopaminergic efflux (Clarke and Pert, 1985; Weiner et al, 1990) and the subsequent effect of dopamine (DA) release on striatal ACh interneurons (Berlanga et al, 2005; Consolo et al, 1999). Striatal cholinergic output then further modulates striatal DA efflux (Zhang et al, 2002). Through these mechanisms, the ACh and DA systems seem to coordinate striatal reward in a feed-forward, complementary manner (Zhou et al, 2003).
Preclinical evidence of a function for ACh in drug-related behaviors has been strongest for cocaine (see review in Williams and Adinoff, 2008). Striatal (Berlanga et al, 2003; Crespo et al, 2006; Mark et al, 1999) and hippocampal (Imperato et al, 1996; Smith et al, 2004a; Smith et al, 2004b) increases in ACh are associated with the acquisition of cocaine; in rodents, the run time (how fast an animal runs to obtain a contingent stimulus) is inversely correlated to nucleus accumbens (NAc) ACh release during cocaine acquisition (Crespo et al, 2006), NAc ACh neuronal activation is directly correlated with the amount of cocaine self-administered (Berlanga et al, 2003), and cholinergic input into the amygdala has a function in the cognitive processes involved in the learning and memory of drug-associated cues (Schroeder and Packard, 2004; See et al, 2003). Indirect evidence also suggests that the relevance of ACh to attentional (Robbins, 2002; Sarter et al, 2003) and decision-making (Chen et al, 2004; Ragozzino and Choi, 2004) processes may impact the observed deficits that many cocaine-addicted subjects show in these neurocognitive domains (Adinoff et al, 2007; Horner et al, 1996; Jovanovski et al, 2005). Substance-induced alterations in cholinergic systems, therefore, could reasonably be expected to alter both reward and cognitive systems relevant to the addictive process (Williams and Adinoff, 2008).
There are two major classes of ACh receptors: the nicotinic receptor (nAChR) and muscarinic receptor (mAChR). The relevance of the nAChR to nicotine (Mansvelder et al, 2003) and, more recently, cocaine (Williams and Adinoff, 2008) dependence have been well described. Of equal interest, however, is the impact of the mACh receptor on cocaine-induced reward and administration. The rewarding effects of cocaine are mediated by M5 receptors in the ventral tegmentum (Fink-Jensen et al, 2003; Thomsen et al, 2005; Yeomans et al, 2001) and M5-deficient rats show an attenuation of cocaine-induced conditioned place preference (Fink-Jensen et al, 2003). Several investigators have observed alterations in striatal mACh receptors after chronic cocaine administration (Lipton et al, 1995; Macedo et al, 2004). In addition to the effects of cocaine mediated by dopaminergic efflux, cocaine itself has direct effects on M1 and M2 (Flynn et al, 1992b; Karpen and Hess, 1986; Sharkey et al, 1988b) receptors. In human studies, polymorphisms of the mAChR M2 gene (CHRM2) have recently been shown to be involved in a general externalizing phenotype predictive of substance-use disorders (Dick et al, 2008).
The ACh system, therefore, offers itself as a potential target for pharmacologic manipulation in the treatment of cocaine dependence. Although clinical studies have offered suggestive evidence of such an approach, the direction of change has been puzzling. Early studies reported a decrease in cocaine self-administration in non-human primates after treatment with either physostigmine, an acetylcholinesterase (AChE) inhibitor (de la Garza and Johanson, 1982) (which increases cholinergic activity) or atropine, an mACh antagonist (which presumably decreases ACh activity) (Wilson and Schuster, 1973). De la Garza et al (2008) have also recently reported that the AChE inhibitor, rivastigmine, decreased methamphetamine-induced craving during self-administration in human volunteers. On the other hand, a preliminary study using donepezil, another cholinesterase inhibitor, did not attenuate cocaine use in a treatment-seeking population (Winhusen et al, 2005).
To our knowledge, there have been no published controlled human studies exploring cholinergic receptor functioning in cocaine-dependent subjects. Given the high concentration of cholinergic receptors in the limbic system, particularly in the amygdala and hippocampus, and the importance of this system to rewarding and addictive behaviors, we hypothesized that limbic regions would be significantly altered in cocaine-dependent individuals compared with healthy controls. We used two cholinergic probes to assess cholinergic functioning. Physostigmine, a cholinergic agonist, was used to concurrently assess muscarinic and nAChRs and scopolamine was used to selectively assess mAChRs. We predicted that areas dominant in mAChRs would have opposite regional cerebral blood flow (rCBF) responses to physostigmine and scopolamine. We also expected that regions dominant in nAChRs would show a response to physostigmine, but not scopolamine. The rCBF was measured in response to each of the two probes as well as a saline comparison. Whereas neuroreceptor radiotracers are used to study pre- and post-synaptic sites, rCBF is used to assess the integrated response to receptor-specific probes, including downstream effects. Thus, our paradigm measured the combined muscarinic and nicotinic (with physostigmine) and muscarinic only (with scopolamine) impact on neuronal function at both the receptor site and the downstream neurons influenced by these receptors. We also chose these probes because of their extensive history of safety in human beings and their earlier use in neuroimaging studies, allowing appropriate dosing to be selected.
Twenty-three (12 male) cocaine-addicted and 22 (12 male) healthy control subjects were studied. Cocaine-addicted subjects had a primary DSM-IV diagnosis of cocaine dependence and cocaine was their lifetime drug of choice. They were 1–6 weeks abstinent [range 8–39 days; 27.4 (SD 7.3)], which offered a relatively circumscribed period of abstinence, acclimation to the residential unit, and adequate time for the most marked effects of cocaine withdrawal to subside (Weddington et al, 1990). Cocaine-addicted subjects were recruited from patients requesting treatment for cocaine dependence at the Veteran's Administration Medical Center (n=11), Homeward Bound, (n=4), and Nexus Recovery Center (n=8) in Dallas, Texas. Abstinence was verified throughout their residential program by urine drug screens at least three times a week at the VA Medical Center, random screens at least weekly and after all passes at Homeward Bound, and random screens at least every 2 weeks and after all passes at Nexus Recovery Center. Addicted subjects were hospitalized as soon as possible after their last reported use of cocaine and remained in a structured, residential unit until the study was completed. Exclusion criteria included a substance-use disorder (other than cocaine or nicotine) within the earlier 6 months, present use of any central nervous system (CNS) active medications, or a lifetime history for affective, anxiety, or schizophrenic disorder, or organic brain syndrome experienced before the onset of a substance-abuse diagnosis or after a period of at least 3 months abstinence. Exclusion criteria for healthy controls included the criteria as noted for the cocaine-addicted subjects, as well as a lifetime history of any other Axis I disorder (except nicotine dependence) or a first-degree relative with an addictive disorder (other than nicotine).
After providing a complete description of the study to the subjects, written informed consent was obtained. Subjects were financially compensated for their participation. Approval for the study was obtained from the Institutional Review Board of the University of Texas Southwestern Medical Center at Dallas (UTSW) and the VA North Texas Health Care System. Subjects underwent a medical history and physical examination, DSM-IV structured clinical interview (First et al, 2002), clinical laboratory tests, urine drug screen, electrocardiogram, narrow-angle glaucoma screening, and clinical MRI. Lifetime cocaine and other substance-use history was obtained from cocaine-dependent subjects using the time line follow back (Sobell and Sobell, 1978).
Study sessions took place at the Clinical Trials Office at the UTSW. Cocaine-addicted subjects were transported directly from their treatment program. Subjects underwent four study sessions over a 10-day period. For one session, only a saline placebo was administered; for the other sessions, subjects received either physostigmine, scopolamine, or ondansetron (ondansetron data not presented here). Sessions were separated by at least 48h to allow time for decay of 99mTcHMPAO, which has a half-life of ~6h. The four scans were administered in a pseudorandom order to assure randomization and to avoid having the two cholinergic probes administered back to back. Thus, at least 96h separated the physostigmine and scopolamine scans. Owing to technical problems, a physostigmine scan was not obtained on one cocaine-addicted subject and scopolamine scans were not obtained on two control subjects.
Nicotine-dependent subjects were allowed a cigarette 30min before study initiation (~2h before radioligand administration). This timing was long enough to avoid the acute effects of nicotine, whereas short enough to avoid the onset of nicotine withdrawal. Subjects were placed supine in a recliner, at rest, with eyes open, and ears unplugged. An intravenous catheter was inserted at ~1400 hours (T=−30min) and a continuous infusion of saline was given throughout the study (except when medication was being administered). The Brief Symptom Inventory (BSI) (Derogatis and Melisaratos, 1983) was administered after 30min of rest (T=0) and just before radioligand administration. The BSI uses 53 questions to assess cognitive, sensory, and affective changes. Blood pressure and heart rate were obtained every 10min throughout the study and vagal tone was recorded continuously (data not reported here). Medications were administered through the intravenous line hidden behind a curtain, and all subjects and the study coordinator were blinded to study drug.
Physostigmine was administered as described by Furey et al (2000) (Figure 1). Glycopyrrolate, a cholinergic antagonist that does not have central effects, was administered 5min before physostigmine (T=0) to block physostigmine's peripheral side effects (ie nausea). Owing to physostigmine's short half-life (~20min), a loading dose of 1.93mg/h × 10min was then administered to achieve steady-state levels (T=5–15), followed by a maintenance rate of 0.816mg/h for 50min (T=15–65). Scopolamine 4.5μg/kg, or 0.315mg for 70kg person, was administered at T=5min by intravenous push over 1min and 55min before radioligand administration (Ahveninen et al, 1999; Blin et al, 1994b; Meador et al, 1995a, 1995b). The long half-life of scopolamine (9.5h) allowed a single bolus to be infused. A total of 20mCi of the single photon emission-computed tomography (SPECT) rCBF tracer 99mTc HMPAO (GE Healthcare, Princeton, New Jersey, USA) was then administered over 30s and followed by a 10ml saline flush over 30s at T=60min. Twenty minutes after the radioligand infusion, the intravenous catheter(s) was removed and a Subjective Symptom Inventory was obtained. The Subjective Symptom Inventory asked subjects to rate (from 0 to 5) 20 signs and symptoms (ie shakiness, blurred vision, headache, sadness, anxiety, drowsiness, etc.) potentially experienced during the study. SPECT scans were obtained 90min after 99mTc HMPAO administration to allow time for tracer activity to clear from blood and non-brain tissues. As 99mTc HMPAO is extracted during the first arterial pass and remains distributed in the brain in proportion to rCBF for many hours, this perfusion image represents rCBF at the time of radiotracer administration and not at the time of the scan.
SPECT images were acquired on a PRISM 3000S three-headed SPECT camera (Picker International, Cleveland, OH, USA) using ultra-high-resolution fan-beam collimators (reconstructed resolution of 6.5mm) in a 128 × 128 matrix in three-degree increments. For our system, voxels in reconstructed images were 1.9mm3. Reconstructed images were smoothed with a sixth-order Butterworth three-dimensional filter, and attenuation corrected using a Chang first-order method with ellipse size adjusted for each slice.
Demographic and clinical characteristics were compared using ANOVA F or χ2 tests as appropriate. Basal and medication-induced (post- vs pre-infusion) changes in BSI, heart rate, and blood pressure were assessed using ANOVA F tests. False discovery rate techniques (Benjamini and Hochberg, 1995) were used to control the type I error rate for the large number of comparisons.
SPECT images were resliced to 2mm3 voxels, co-registered to Montreal Neurologic Institute (MNI) space using the MNI T1 MRI template, smoothed to a final resolution of 10mm and normalized to whole brain counts (to correct for individual variability in global cerebral blood flow). Relative rCBF in healthy subjects has low variance across subjects and is relatively stable over time within subjects (Devous, 2002). The accuracy of spatial normalization of functional brain images (SPECT, PET, and fMRI) is limited by the spatial resolution of the original data (6mm for these data), by partial volume effects, and by the limits of the normalization algorithm used. Thus, the accuracy of normalization in our data is about 2–4mm, and the anatomic designations assigned to observed rCBF effects are constrained by these limitations, as well as by our spatial resolution and partial volume effects.
Voxel-wise analyses (voxel Z-scores=p<0.005, cluster size>100 voxels) comparing saline- and physostigmine/scopolamine-induced effects were conducted using Statistical Parametric Mapping (SPM2; University College, London, England). Significant changes induced by physostigmine and scopolamine were computed relative to saline. Between-group differences after physostigmine and scopolamine were also assessed (p<0.005, cluster size>50).
Regions of interest defined by cluster boundaries for eight regions we considered relevant to addictive processes were also identified and the average rCBF within each cluster was determined for each subject in each condition. Group differences were obtained by t-test and Pearson product moment correlation was used to assess the association between clusters and cocaine or nicotine use in cocaine-addicted subjects. As comparisons are for relative measures, they cannot identify the absolute direction of differences. For example, a heightened rCBF response in cocaine-addicted subjects compared with controls may indicate a greater relative increase in rCBF in cocaine-addicted subjects compared with controls, a greater decrease in rCBF response in controls relative to cocaine-addicted subjects, or a combination of both. Owing to the decreased power of a contrast of differences requiring significant differences both within and between groups, cluster size was lowered to 50 voxels. To clarify the direction of change observed in the between-group comparisons, within-group comparisons were also performed at less conservative p-values (p<0.05, <0.01) to identify whether controls or cocaine-addicted subjects were driving the between-group differences.
Regions of interest defined by cluster boundaries for eight regions we considered relevant to addictive processes were also identified and the average rCBF within each cluster was determined for each subject in each condition. Group differences were obtained by t-test and Pearson product moment correlation was used to assess the association between clusters and cocaine or nicotine use in cocaine-addicted subjects.
Control and cocaine-addicted populations were gender matched (see Table 1) and did not significantly differ in race or age. The cocaine-addicted group had more smokers (22/23 smoked) relative to the control group (6/22 smoked) and a lower mean level of education.
After administration of the cholinergic agonist physostigmine, compared with saline, control subjects (n=22) showed a relative rCBF decrease in right amygdala, right dorsolateral prefrontal cortex (DLPFC), and right anterior cingulate (Figure 2, top panel; Table 2). Cocaine-addicted subjects (n=22) (Figure 2, middle panel) showed an rCBF decrease in left posterior hippocampus (cluster overlaps hippocampal tail) and left amygdala, and an increase in right posterior insula. Hippocampal changes are illustrated in further detail in Figure 3 along with individual subject data.
Comparisons between groups (Figure 2, lower panel) showed that cocaine-addicted relative to control subjects had decreases in left hippocampus and posterior cingulate and increases in right posterior insula, middle temporal gyrus, DLPFC, and a region of the posterior cingulate posterior to where the decrease is located. A comparison of the top and middle panels of Figure 2 indicates that the DLPFC increase seen in the bottom panel is primarily a consequence of decreases in rCBF in the region experienced by normal controls, whereas the increase in right insula is driven by increases in the area in the addicted subjects. Similarly, the decrease in left posterior hippocampus is driven by changes in the cocaine-addicted group. Left posterior cingulate increases and decreases were driven by changes evident only at a p<0.01 threshold; controls increased and cocaine-addicted subjects decreased rCBF in nearly identical regions.
SPM-derived clusters showed a significant difference between groups in three predicted limbic regions [left posterior hippocampus/hippocampal tail (p=0.027), left amygdala (p=0.027), right posterior insula (p=0.005)] as well as in the limbically innervated right DLPFC (p=0.005) (Table 3).
After scopolamine relative to saline, the posterior hippocampus/left hippocampal region again showed decreased rCBF in cocaine-addicted subjects (n=23) (Figure 4, middle panel; Table 4). Note the striking similarity in the response in posterior hippocampus in addicted subjects for both physostigmine and scopolamine. In fact, cocaine-addicted subjects showed a significant correlation between physostigmine and scopolamine rCBF in this region (r=0.62, df=22, p<0.002). Non-limbic regions showing scopolamine-induced rCBF changes in controls (Figure 4, top panel) included right DLPFC and left posterior cingulate (increases) and right thalamus and medial orbitofrontal cortex (decreases). Cocaine-addicted subjects also showed significant rCBF changes in left DLPFC, an area adjacent to left anterior cingulate (increases), and left midbrain (overlapping substantia nigra and ventral tegmentum) and areas in bilateral thalamus (decreases).
Between-group comparisons (Figure 4, bottom panel) showed relative group differences in right anterior insula and left posterior cingulate. This posterior cingulate region is nearly identical to that seen in the between-group physostigmine comparison. Although scopolamine-induced large decreases in bilateral thalamic rCBF, there were no significant differences between groups. Further analyses of selected SPM-derived clusters showed a significant difference between groups in left posterior hippocampus (p=0.027) and midbrain (p=0.027), and left posterior cingulate (p=0.01) and right anterior insula (p=0.005) (Table 3).
There were no significant baseline-group differences in subjective symptoms. Of the 20 subjective symptoms, physostigmine only significantly increased dry mouth relative to saline, presumably because of the glycopyrrulate (Table 5). Scopolamine increased symptoms typically associated with anticholinergic medications, including dry mouth, blurred vision, dizziness, and drowsiness. There were no significant differences between groups.
Scores showed minimal changes after these probes (Table 6). Only somatization after scopolamine in controls increased post-relative to pre-infusion (p<0.005, unadjusted). Between-group comparisons revealed only relative increases in somatization and global severity index in control (p<0.05) and decreases in depression in cocaine-addicted (p<0.05) subjects.
There were no significant (multimeasure unadjusted) between-group differences in systolic or diastolic blood pressure or heart rate after any of the three infusions (Table 7). In controls, there was a significant (unadjusted) increase in heart rate after saline (p<0.042) and decreases in heart rate after both physostigmine (p<0.0004) and scopolamine (p<0.0001). In cocaine-addicted subjects, an increase in diastolic blood pressure was observed after saline and a decrease in heart rate after scopolamine (p<0.006).
To assess whether the amount of cocaine or nicotine use impacted image data, correlation analyses (unadjusted p<0.05) were performed on clinically relevant clusters, as defined by differences after physostigmine or scopolamine, and cocaine (lifetime days used, lifetime amount used, days used in earlier 90 days) and nicotine (lifetime pack years, cigarettes per day at time of assessment) use variables. There were no significant correlations between cocaine use variables and the eight selected regions of interest. Cigarette lifetime pack years was associated (unadjusted p-value) with rCBF in right posterior (r=0.45, df=21, p=0.035) and anterior insula (r=−0.57, df=21, p=0.006). Cigarettes/day was significantly associated with rCBF in right anterior insula (r=−0.63, df=21, p=0.002).
Cocaine-addicted subjects differed from controls in their neural response to cholinergic probes in discrete limbic regions, including hippocampus, amygdala, and insula. These regions are important in the learning and memory of drug cues and associated craving. Other relevant responding regions included midbrain (including ventral tegmentum), DLPFC, orbitofrontal cortex, posterior cingulate, and middle temporal gyrus. These findings suggest a disruption in cholinergic receptor systems, particularly mAChRs, in abstinent cocaine-addicted subjects compared with healthy controls similar in age, sex, and race. Although the multiple sources of cholinergic afferents and the presence of both inhibitory and excitatory mACh/nACh receptor subtypes currently prohibit an integrated, cohesive explanation for the regional differences observed, our findings reveal a significant alteration in cholinergic mechanisms in cocaine-addicted subjects.
We found a mix of both increased and decreased rCBF after both physostigmine and scopolamine. Earlier studies suggesting that physostigmine did not significantly alter rCBF in healthy controls suffered from subthreshold doses of physostigmine (Blin et al, 1994b; Geaney et al, 1990) or relatively insensitive measures of cerebral blood flow (Gustafson et al, 1987). Although Blin et al (1997, 1994a) used a maintenance physostigmine and bolus scopolamine dosing strategy somewhat similar to ours, this group reported consistent decreases in regional glucose consumption after physostigmine and generalized increases with scopolamine in healthy controls. The most striking difference in methodology is our use of functionally derived ROIs compared with Blin et al's use of larger anatomically derived ROIs, allowing us substantially more rigor in isolating specific areas of neural change.
The mix of increased and decreased rCBF after either physostigmine or scopolamine indicates that the use of these two probes, while affecting relatively specific brain regions with high concentrations of ACh terminals, do not induce straightforward changes in rCBF. In addition, some regions with particularly high concentrations of cholinergic receptors (ie amygdala, hippocampus) showed no or limited rCBF changes in control subjects after either probe. These findings emphasize the difficulty in isolating specific cholinergic receptor systems in vivo, even using probes specific to the cholinergic system, and is likely due to the mix of inhibitory and excitatory nicotinic and muscarinic subtypes and the complex interplay between these inputs (Zhou et al, 2003). For example, an equal distribution of excitatory and inhibitory cholinergic receptors in a brain region would result in a relative absence of rCBF change after physostigmine, as the two opposing directional changes would effectively cancel each other out. As detailed below, however, a relative increase or decrease in either inhibitory or excitatory cholinergic receptors after chronic cocaine use could result in a net change in rCBF.
A combination of inhibitory and excitatory receptor subtypes could also underlie the apparent unidirectional changes in rCBF that occasionally occurred in a discrete region after physostigmine and scopolamine. For example, the left posterior hippocampus was decreased in the cocaine-addicted group in response to both medications. We had predicted that the use of a cholinergic mAChR and nAChR agonist (physostigmine) and mAChR antagonist (scopolamine) would push rCBF activation in opposite directions and allow the delineation between mAChR and nAChR systems. A possible explanation of our findings may lie in the prevalence of both post-synaptic excitatory M1 receptors and M2 inhibitory pre-synaptic autoreceptors in the hippocampus. A relative decrease in M1 excitatory hippocampal receptor number or affinity after chronic cocaine use would produce an rCBF decrease after the administration of both physostigmine (because of attenuated stimulation of excitatory receptors relative to inhibitory autoreceptors) and scopolamine (because of more effective blockade of fewer excitatory receptors), consistent with our findings. Similarly, a relative increase in M2 hippocampal receptors in cocaine-addicted subjects would induce a decrease in rCBF after the administration of both physostigmine (because of relatively greater ACh stimulation of inhibitory autoreceptors) and scopolamine (because of a more ineffective blockade of increased inhibitory autoreceptors).
One of the most discrete findings, and of critical relevance to the addictive process, was the group difference observed in the posterior hippocampus in a cluster that includes the hippocampal tail, after both physostigmine and scopolamine. Using multidirectional high-resolution MRI images in the rat, cat, dog, and human Sasaki et al (2004) concluded that the hippocampal tail in the human brain is homologous to the non-primate dorsal hippocampus. The dorsal hippocampus is required for contextual conditioning during cocaine administration. For example, lesions of the dorsal hippocampus disrupt both the acquisition and expression of cocaine conditioned place preference in the rodent (Meyers et al, 2006) and Crombag et al (2008) have posited a function for a serial relationship between the dorsal hippocampus, basolateral amygdala, dorsal striatum, and dorsal medial PFC in context-induced drug reinstatement. Contextual learning processes are mediated, at least in part, by cholinergic receptors and the hippocampus has among the highest concentrations of ACh in the CNS. Hippocampal ACh receptors are primarily muscarinic; drugs that block mAChRs, such as scopolamine, impair the encoding of new information (Hasselmo, 1995) and hippocampal M2 knock-out mice show a dramatic decrease in long-term potentiation (Seeger et al, 2004). Given the dopaminergic influence on hippocampal cholinergic output (Imperato et al, 1993b), it is reasonable to assume that chronic cocaine use could alter hippocampal cholinergic receptors. In fact, extracellular and turnover rates of hippocampal ACh are increased after acute cocaine administration (Imperato et al, 1993a; Imperato et al, 1996; Robinson and Hambrecht, 1988; Smith et al, 2004b) and 5 days of cocaine administration significantly decrease hippocampal mACh receptor binding (Zeigler et al, 1991). Thus, the extant literature would suggest that the observed hippocampal alterations in cocaine-addicted subjects could be a result of chronic cocaine use and that disruptions in dorsal hippocampal cholinergic regulation could alter the ability of cocaine-addicted subjects to extinguish cocaine-cued learning. Enhancement of hippocampus neurogenesis by a cholinergic agonist (Kotani et al, 2008), a process inhibited by chronic cocaine administration (Noonan et al, 2008; Yamaguchi et al, 2004), also points to putative function of the cholinergic system in cocaine-induced hippocampal functioning.
Other relevant regions of differing rCBF responses included the insular cortex, ACC, and DLPFC, with the insular cortex and DLPFC reaching our statistical threshold for differences between groups. Unlike the hippocampal ACh projections, which arise primarily from the medial septum-vertical diagonal band of Broca (Ch1 and Ch2), the cortex (and amygdala) receives cholinergic projections mainly from the nucleus basalis of Meynert (Ch4) (Mesulam, 1996). All of these regions have been implicated in the craving response to cocaine. The response of the insula was of particular interest. The cocaine-addicted group, relative to controls, showed an increased rCBF response in the posterior insula after physostigmine and the anterior insula after scopolamine. The insula, particularly the anterior insula, is preferentially involved in the evaluative, experiential, or expressive aspects of internally generated emotions (Craig, 2003; Reiman et al, 1997). The insula is frequently noted to be active during cocaine craving (Bonson et al, 2002; Garavan et al, 2000; Kilts et al, 2001) and lesions of the insula, particularly on the right side of the brain, has been associated with the dissolution of craving in nicotine-addicted subjects (Naqvi et al, 2007). Right insular activation during a two-choice prediction task has also been associated with relapse in methamphetamine-dependent subjects (Paulus et al, 2005). The DLPFC, a key area for working memory and also frequently activated during cocaine craving (Grant et al, 1996; Maas et al, 1998), also showed rCBF differences between groups after both infusions.
A rather large area of the left MTG showed increased rCBF after physostigmine in cocaine-addicted subjects relative to controls. Given the connections of the MTG with other temporal lobe structures, including the hippocampus, a function for this region in aspects of declarative memory has been suggested. However, the relationship of the MTG to cocaine addiction is not immediately apparent. Nevertheless, a number of earlier investigators have identified alterations in the MTG in cocaine-addicted populations under a variety of paradigms. Risinger et al (2005) found significant correlations between cocaine-induced anxiety and MTG activation, Paulus et al (2005) reported a correlation between relapse and MTG activation in methamphetamine-dependent subjects, and Kosten et al (2006) noted a relationship between MTG activation during cue-induced craving and treatment outcome. Thus, the MTG may have functions relevant to cocaine addiction distinct from its function in declarative memory.
A region of the left posterior cingulate cortex (PCC) was of particular interest. PCC activation has been associated with craving (Li et al, 2005) or relapse risk (Paulus et al, 2005) in both cocaine- and methamphetamine-addicted subjects. The dorsal PCC changes identified a similar location of decreased rCBF after both physostigmine (−16, −26, 50; 251) (Figure 2, bottom panel) and scopolamine (−18, −26, 54; 131) (Figure 4, bottom panel).
All but three of our cocaine-addicted subjects were smokers, and all but six of the controls were non-smokers; five of these six controls were very light smokers. This confound generally plagues most clinical laboratory research of substance abusers, as most drug-dependent patients smoke and most healthy volunteers without medical or psychological morbidity do not. Nevertheless, there are several reasons supporting the function of cocaine use, as opposed to just nicotine use, in our findings.
First, scopolamine, a mAChR receptor antagonist, showed significant group differences. This probe would not have been expected to be particularly sensitive to nicotine-induced changes acting directly on nAChRs. In addiction, cocaine, unlike nicotine, has been shown to bind directly with mAChRs (Flynn et al, 1992a; Sharkey et al, 1988a) and cocaine administration alters mAChRs in preclinical models (Lipton et al, 1995; Sousa et al, 1999; Zeigler et al, 1991). Second, Brody et al (2006) has observed that nAChRs remain occupied by nicotine for several hours after smoking in nicotine-dependent subjects. As our nicotine-dependent subjects smoked a cigarette 2h before infusion, their nAChRs may have been relatively resilient to the effects of physostigmine-induced elevations in ACh and thus reflect primarily mAChR systems. Third, our small sample of cocaine-addicted non-smokers and controls smokers did not suggest a nicotine-relevant effect (Figure 3). Finally, a recent study by Easwaramoorthy et al (2007) reveals that physostigmine infusion, in the absence of an additional infusion of ACh, does not alter α4β2 nAChR binding. On the other hand, Carson et al (1998) found that the administration of physostigmine to non-human primates produced a 35% decrease in mAChR cortical binding.
That being said, nicotine itself may alter mAChRs. For instance, acute administration studies show that nicotine directly alters rCBF in regions observed after both physostigmine and scopolamine infusion in this study, including the hippocampus, anterior and posterior cingulate, and insula (Domino et al, 2000a; Domino et al, 2000b; Rose et al, 2003; Zubieta et al, 2005). The relevance of nicotine dependence to our findings would best be answered by a similar study in healthy controls with nicotine dependence. Although an assessment of cocaine-addicted subjects without nicotine dependence might be of academic interest, given the high co-morbidity of nicotine and cocaine dependence (Kalman et al, 2005), such a study would have little clinical relevance and may miss a critical interactive effect between nicotine and cocaine.
A major strength of our study was the use of age-, sex-, and race-similar cocaine-addicted and control subjects. Cocaine-addicted subjects did not have other active drug use disorders (except nicotine) and were studied during a defined period of verified abstinence, thus avoiding the rapid fluctuations in neural activity that occur during the first few days of cocaine abstinence as well as the more gradual changes that may develop with extended abstinence. Menstrual cycles were not controlled because of the several days required to conduct multiple infusions. Although central cholinergic neurons can be altered by estrogen (Smith et al, 2001), human studies show that nAChRs (containing b2-subunits) do not change over the menstrual cycle (Cosgrove et al, 2007). Both infusions provoked relatively specific rCBF responses with minimal, if any, adverse effects. Although physostigmine is relatively non-specific, most likely reflecting both pre- and post-synaptic cortical cholinergic transmission (Bohnen and Frey, 2007), it does reduce 40–50% of AChE activity in healthy volunteers (Koeppe et al, 1997). Neither an age nor a gender effect of cortical AChE activity is present in healthy controls (Kuhl et al, 1999; Namba et al, 1999), making physostigmine a relatively stable measure to compare groups.
Limits of spatial resolution and the ability to only determine relative measures of limbic activation are inherent in our SPECT methodology and camera. It should also be noted that the SPECT technique used assessed relative (to whole brain), not absolute, rCBF differences between groups. Although volumetric reductions have been reported in cocaine-addicted subjects (Bartzokis et al, 2002; Franklin et al, 2002; Lim et al, 2002; Matochik et al, 2003) relative to controls, no discrete structural lesions (by MRI) were observed in any of the subjects in this study. However, we cannot rule out the possibility that regions of muted rCBF responses observed in cocaine-addicted subjects resulted from neuronal loss. Further, areas differing between groups after the pharmacologic probes could actually be abnormal at baseline. However, regions earlier reported to show baseline differences in rCBF (Adinoff et al, 2006) generally differ from those identified between cocaine-addicted and control subjects in our data.
Finally, there are inherent errors in spatial normalization for all functional imaging techniques, thus limiting the precision of our anatomic identifications. Further, SPECT imaging is limited to a reconstructed resolution of about 6mm, and for our analyses, this was further smoothed to 10mm, and suffers from partial volume effects as well. Thus, anatomic labeling of significant clusters should be interpreted cautiously. It is also true that there are reports of inherent variability over time in rCBF measures (modest in healthy controls, but less well studied in patient populations). The effects are generally random among subjects, but it cannot be entirely ruled out that some of our observations are affected by this inherent day-to-day variability in rCBF.
This is, to our knowledge, the first human study to reveal differences in central cholinergic functioning of cocaine-addicted subjects compared with healthy controls. Furthermore, these differences are in regions known to be heavily cholinergically innervated and highly relevant to the addictive process. Although rCBF with SPECT is highly useful in eliciting the integrated CNS response to a receptor-specific pharmacologic challenge, a variety of highly specific muscarinic and nAChR imaging agents will be necessary in delineating specific receptor alterations in cocaine-addicted subjects. Our work provides a sound rationale for investigating specific nAChR and mAChR changes as well as cholinergic pharmacologic approaches in the addictions.
We thank the staff of the Substance Abuse Team at the VA North Texas Health Care System, Homeward Bound, and the Nexus Recovery Center for their support in the screening and recruitment of study subjects. Dr Adinoff had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This study was funded by NIH DA11434 and supported by the VA North Texas Health Care System. Ceretec (HMPAO) was generously supplied by GE Healthcare.
Bryon Adinoff has received grant/research support from the NIAAA, NIDA, Department of Veterans Affairs. He has served as Consultant: Pain Insights, medical malpractice consultant to Conroy, Simberg, Ganon, Krevans & Abel, PA; as advisor to GlaxoSmithKline; as legal consultant to The Hershewe Law Firm, PC; and has received Honoraria: CME, from the Temple University, Texas, Department of State Health Services in 2006. He has served as legal consultant to Phillips Lytle LLP for GSK; as advisor to GlaxoSmithKline; as medical malpractice consultant to The Hershewe Law Firm, PC; and has received Honoraria: from American Academy of Addiction Psychiatry, Medical University of South Carolina in 2007. He also served as medical malpractice consultant to Simon Pissante PC; as advisor to Teva Pharmaceutical Industries; as medical malpractice consultant to Shook, Hardy & Bacon LLP for tobacco companies; and has received Honoraria: from American Academy of Addiction Psychiatry, University of New Mexico in 2008. Michael D Devous has served on the Scientific Advisory Board of AVID Radiopharmaceuticals and also received research support from AVID Radiopharmaceuticals and Alseres. The remaining authors declare no conflict of interest.
Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)